Y-mAbs Therapeutics, Inc.
YMAB
$5.06
-$0.215-4.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -21.10% | 43.52% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.10% | 43.52% | |||
| Cost of Revenue | -61.73% | 248.84% | |||
| Gross Profit | -4.02% | 15.05% | |||
| SG&A Expenses | 7.21% | -9.11% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -14.05% | 17.28% | |||
| Operating Income | -28.79% | 44.42% | |||
| Income Before Tax | 31.17% | -13.38% | |||
| Income Tax Expenses | 100.66% | -317.34% | |||
| Earnings from Continuing Operations | 23.48% | 2.97% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 23.48% | 2.97% | |||
| EBIT | -28.79% | 44.42% | |||
| EBITDA | -30.20% | 44.87% | |||
| EPS Basic | 23.86% | 3.51% | |||
| Normalized Basic EPS | 28.88% | 0.00% | |||
| EPS Diluted | 24.26% | 3.00% | |||
| Normalized Diluted EPS | 28.88% | 0.00% | |||
| Average Basic Shares Outstanding | 0.51% | 0.56% | |||
| Average Diluted Shares Outstanding | 0.51% | 0.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||